Improved High-Performance Liquid Chromatographic Method for the Determination of Indomethacin in Plasma

Ag, Johnson; Je, Ray

doi:10.1097/00007691-199202000-00010

Cited by 21 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The culture medium was removed and replaced with medium containing either piroxicam or indomethacin at 5 mg/ml for 2 h, the cells washed twice with phosphate buVered saline and then spun down. The pelleted cells were then analysed by separate HPLC methods for piroxicam or indomethacin ( [42] and [43], respectively). Data are expressed as the non-steroidal anti-in¯ammatory drug (NSAID) content of 10…”

Section: Glutathione-s-transferase Assaysmentioning

confidence: 99%

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

Duffy

Elliott

O’Connor

et al. 1998

European Journal of Cancer

228

151

View full text Add to dashboard Cite

The eVect on cytotoxicity of combining a range of clinically important non-steroidal anti-in¯amma-tory drugs (NSAIDs) with a variety of chemotherapeutic drugs was examined in the human lung cancer cell lines DLKP, A549, COR L23P and COR L23R and in a human leukaemia line HL60/ADR. A speci®c group of NSAIDs (indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) all at non-toxic levels, signi®cantly increased the cytotoxicity of the anthracyclines (doxorubicin, daunorubicin and epirubicin), as well as teniposide, VP-16 and vincristine, but not the other vinca alkaloids vinblastine and vinorelbine. A substantial number of other anticancer drugs, including methotrexate, 5-¯uorouracil, cytarabine, hydroxyurea, chlorambucil, cyclophosphamide, cisplatin, carboplatin, mitoxantrone, actinomycin D, bleomycin, paclitaxel and camptothecin, were also tested, but displayed no synergy in combination with the NSAIDs. The synergistic eVect was concentration dependent. The eVect appears to be independent of the cyclo-oxygenase inhibitory ability of the NSAIDs, as (i) the synergistic combination could not be reversed by the addition of prostaglandins D 2 or E 2 ; (ii) sulindac sulphone, a metabolite of sulindac that does not inhibit the cyclooxygenase enzyme, was positive in the combination assay: and (iii) many NSAIDs known to be cyclo-oxygenase inhibitors, e.g. meclofenamic acid, diclofenac, naproxen, fenoprofen, phenylbutazone,¯ufenamic acid,¯urbi-profen, ibuprofen and ketoprofen, were inactive in the combination assay. The enhancement of cytotoxicity was observed in a range of drug sensitive tumour cell lines, but did not occur in P-170-overexpressing multidrug resistant cell lines. However, in the HL60/ADR and COR L23R cell lines, in which multidrug resistance is due to overexpression of the multidrug resistance-associated protein MRP, a signi®cant increase in cytotoxicity was observed in the presence of the active NSAIDs. Subsequent Western blot analysis of the drug sensitive parental cell lines, DLKP and A549, revealed that they also expressed MRP and reverse-transcription±polymerase chain reaction studies demonstrated that mRNA for MRP was present in both cell lines. It was found that the positive NSAIDs were among the more potent inhibitors of [ 3 H]-LTC 4 transport into inside-out plasma membrane vesicles prepared from MRP-expressing cells, of doxorubicin eZux from preloaded cells and of glutathione-Stransferase activity. The NSAIDs did not enhance cellular sensitivity to radiation. The combination of speci®c NSAIDs with anticancer drugs reported here may have potential clinical applications, especially in the circumvention of MRP-mediated multidrug resistance. #

show abstract

Section: Glutathione-s-transferase Assaysmentioning

confidence: 99%

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

Duffy

Elliott

O’Connor

et al. 1998

European Journal of Cancer

228

151

View full text Add to dashboard Cite

show abstract

“…The HPLC system was composed of two LC-10AD VP pumps, an SPD-10A VP ultraviolet detector, and an SIL-10AD VP autosampler from Shimadzu (Kyoto, Japan). The analysis was performed as previously described 8) on an octadecylsilica (ODS) column (150 mm×4.6 mm i.d.) with 5-mm particle size (Wakopak, Wakosil-II 5C18, Wako Pure Chemical Industries).…”

Section: In Vitro Adhesion Testmentioning

confidence: 99%

<i>In Vitro</i> and Clinical Evaluation of an Oral Mucosal Adhesive Film Containing Indomethacin

et al. 2008

View full text Add to dashboard Cite

To develop a new mucoadhesiveˆlm containing an analgesic combining clinical e‹cacy and patient comfort, we prepared and evaluated a two-layeredˆlm consisting of an adhesive layer containing indomethacin (IM) as the active ingredient and carboxyvinyl polymer (CP) as a bonding agent and a nonadhesive layer containing polyethylene glycol (PEG) to improveˆlm texture. In in vitro and in vivo adhesive tests, the optimal concentration of CP that could be applied to the mucous membrane was 0.2％ or 0.3％. Stability testing determined that the optimal storage conditions and expiration period were 4°C without shade and 4 weeks, respectively. Theˆlm was clinically evaluated in patients with oral pain. IM at concentrations of 0.5％ and 1％ provided optimum analgesic eŠects, and the eŠects were the greatest in the 1％ IM group. The addition of PEG to the nonadhesive layer reduced the number of patients experiencing discomfort at the site where theˆlm was applied. Therefore thisˆlm formulation may be useful for local analgesic application due to its low dose requirement, moderate adhesion, and comfortable texture.

show abstract

“…Numerous methods are available for the determination of indomethacin, including gas chromatography (GC) [4,5], GC-mass spectrometry [6], high performance liquid chromatographic (HPLC) methods [7][8][9][10][11][12][13][14][15][16][17][18], HPLC-mass spectrometry [19,20] and capillary electrophoresis (CE) [21][22][23][24][25]. Indomethacin has an active carboxyl group in the structure.…”

Section: Introductionmentioning

confidence: 99%

Determination of indomethacin in plasma by micellar electrokinetic chromatography with UV detection for premature infants with patent ducts arteriosus

Lin

Chen

et al. 2006

Journal of Chromatography B

View full text Add to dashboard Cite

Improved High-Performance Liquid Chromatographic Method for the Determination of Indomethacin in Plasma

Cited by 21 publications

References 0 publications

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs)

<i>In Vitro</i> and Clinical Evaluation of an Oral Mucosal Adhesive Film Containing Indomethacin

Determination of indomethacin in plasma by micellar electrokinetic chromatography with UV detection for premature infants with patent ducts arteriosus

Contact Info

Product

Resources

About